News
CARA
--
0.00%
--
Cara Therapeutics Granted U.S. Patent Titled 'Oral formulations of kappa opioid receptor agonists'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6620&f=G&l=50&d=PTXT&p=133&S1=20210615&OS=20210615&RS=20210615
Benzinga · 6d ago
BRIEF-Swk Holdings' Subsidiary, Enteris Biopharma, Receives $10 Million Milestone Payment From Cara Therapeutics
reuters.com · 06/11 12:44
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $10 million milestone pa...
PR Newswire · 06/11 11:30
SWK Unit Receives $10 Million Milestone Payment From Cara Therapeutics
MT Newswires · 06/11 08:40
Could The Cara Therapeutics, Inc. (NASDAQ:CARA) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
Simply Wall St. · 06/10 06:02
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels
PALM BEACH,  Fla., /PRNewswire/ --  The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-19 pandemic outbrea...
PR Newswire - PRF · 06/08 12:30
Cara Therapeutics: Return On Capital Employed Insights
During Q1, Cara Therapeutics (NASDAQ:CARA) brought in sales totaling $1.94 million. However, earnings decreased 130.09%, resulting in a loss of $23.56 million. Cara Therapeutics reached earnings of $78.29 million and sales of $112.09 million in Q4.
Benzinga · 06/03 15:15
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies (Updated)
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.
Benzinga · 05/27 14:36
Cara Therapeutics to Present at the Jefferies Healthcare Conference
STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa o...
GlobeNewswire · 05/25 11:00
Ikarian Capital, LLC Buys Eli Lilly and Co, Macrogenics Inc, Galapagos NV, Sells Bristol-Myers ...
GuruFocus News · 05/17 12:38
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.
Benzinga · 05/14 18:21
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
Cannabis Stock Gainers And Losers From May 11, 2021
GAINERS: Claritas Pharmaceuticals (OTC: KALTF) shares closed up 35.6% at $0.03
Benzinga · 05/11 21:02
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 05/11 11:54
Needham Gives a Buy Rating to Cara Therapeutics (CARA)
Needham analyst Joseph Stringer assigned a Buy rating to Cara Therapeutics (CARA) today and set a price target of $26.00. The company's shares closed last
SmarterAnalyst · 05/11 11:05
H.C. Wainwright Thinks Cara Therapeutics’ Stock is Going to Recover
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Cara Therapeutics (CARA), with a price target of $33.00. The
SmarterAnalyst · 05/11 10:16
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 05/10 21:35
BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.47
reuters.com · 05/10 21:09
Cara Therapeutics: Q1 Earnings Insights
Shares of Cara Therapeutics (NASDAQ:CARA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 24.19% year over year to ($0.47), which beat the estimate of ($0.59).
Benzinga · 05/10 20:49
Webull provides a variety of real-time CARA stock news. You can receive the latest news about Cara through multiple platforms. This information may help you make smarter investment decisions.
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.